Expedition Therapeutics secured a $115 million Series B financing tied to advancing its oral COPD candidate EXPD-101 through phase II. The company said the round supports clinical execution in its ongoing phase II study (NCT07684820), with dosing already underway following “first patient dosed” progress. Expedition’s therapy is designed to target neutrophilic inflammation through inhibition of DPP1, positioned as a driver of COPD exacerbation risk across the disease spectrum. The company said the candidate has shown tolerability in phase I, with pharmacokinetics supporting once-daily oral administration. The financing also signals renewed risk appetite in respiratory small-molecule development and provides capital for further pipeline and platform expansion tied to clinical milestone delivery.